Financial Contrast: Moleculin Biotech (NASDAQ:MBRX) vs. Dogwood Therapeutics (NASDAQ:DWTX)

Dogwood Therapeutics (NASDAQ:DWTX) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.

Volatility and Risk

Dogwood Therapeutics has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

Earnings and Valuation

This table compares Dogwood Therapeutics and Moleculin Biotech”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$12.35 million	($24.93)	-0.21
Moleculin Biotech	N/A	N/A	-$21.76 million	($3.27)	-0.15

Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dogwood Therapeutics and Moleculin Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	N/A	-34.74%
Moleculin Biotech	N/A	-1,498.41%	-114.47%

Insider and Institutional Ownership

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 3.6% of Dogwood Therapeutics shares are held by company insiders. Comparatively, 3.4% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Dogwood Therapeutics and Moleculin Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1	0	1	0	2.00
Moleculin Biotech	1	0	2	0	2.33

Dogwood Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 128.14%. Moleculin Biotech has a consensus price target of $4.00, suggesting a potential upside of 718.00%. Given Moleculin Biotech’s stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Dogwood Therapeutics.

Summary

Moleculin Biotech beats Dogwood Therapeutics on 6 of the 11 factors compared between the two stocks.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

About Moleculin Biotech

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.